EnsoData
AI-powered software to analyze sleep studies and cardiorespiratory waveform data for sleep disorder diagnosis.
Website: https://www.ensodata.com/
Cover Block
| Name | EnsoData |
| Tagline | AI-powered software to analyze sleep studies and cardiorespiratory waveform data for sleep disorder diagnosis. [EnsoData, retrieved 2026] |
| Headquarters | Madison, Wisconsin, USA |
| Founded | 2015 [StartupIntros, retrieved 2026] |
| Stage | Series B |
| Business Model | SaaS |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding Label | $50M+ (total disclosed ~$50,000,000) [MedCity News, June 2025] |
Links
- Website: https://www.ensodata.com/
- LinkedIn: https://www.linkedin.com/company/ensodata
- Forbes Technology Council (Chris Fernandez): https://www.forbes.com/councils/chrisfernandez/
Executive Summary
EnsoData is a healthtech company using FDA-cleared AI to automate the labor-intensive scoring of sleep studies, addressing a critical bottleneck in diagnosing the estimated 80% of sleep apnea patients who remain undiagnosed [EnsoData, retrieved 2026]. Founded in 2015 by Chris Fernandez, Nick Glattard, and Sam Rusk, the company has built a cloud-based SaaS platform, EnsoSleep, which analyzes polysomnography and home sleep apnea test data to save clinicians an average of 62-68% of scoring time [EnsoData, retrieved 2026]. This operational wedge has attracted over $50 million in total funding, including a recent $20 million Series B led by Questa Capital and a strategic $10 million investment from Inspire Medical Systems [EnsoData, June 2025] [Inspire Medical Systems, Jan 2022].
Leadership transitioned in late 2022 with the appointment of CEO Justin Mortara, while founder Chris Fernandez moved to the role of Executive Chairman and Chief Research Officer. The company’s model targets sleep labs and health systems, aiming to convert time savings into increased patient throughput. Over the next 12-18 months, the key watchpoints will be the commercial expansion funded by the Series B and the depth of integration realized with strategic investor Inspire Medical Systems.
Data Accuracy: GREEN -- Company disclosures, investor press releases, and founder profiles are consistent across multiple independent sources.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Series B |
| Business Model | SaaS |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | $50M+ (total disclosed) |
How the Company Got Here
EnsoData was founded in 2015 in Madison, Wisconsin, by Chris Fernandez, Sam Rusk, and Nick Glattard [StartupIntros, retrieved 2026]. The company's origin is rooted in academic research, focusing on applying machine learning to analyze complex physiological waveforms [EnsoData, retrieved 2026]. A key early milestone was the FDA clearance of its EnsoSleep platform in 2017 [Sleep Review, retrieved 2026].
Justin Mortara joined as CEO in November 2022, with founder Chris Fernandez transitioning to Executive Chairman and Chief Research Officer [EnsoData, retrieved 2026][BizTimes, retrieved 2026]. This transition coincided with a period of strategic growth, following a $10 million strategic minority investment from Inspire Medical Systems [Inspire Medical Systems, Jan 2022]. The founding team was named to the 2021 Forbes 30 Under 30 list in Healthcare [Sleep Review, retrieved 2026].
By 2025, the company reported its EnsoSleep platform was in use at more than 400 clinics across the United States [Sleep Review, retrieved 2026]. In June 2025, EnsoData closed a $20 million Series B financing round led by Questa Capital, bringing its total disclosed funding to approximately $50 million [EnsoData, June 2025][MedCity News, June 2025].
Data Accuracy: GREEN -- Foundational facts confirmed by company website, Crunchbase, and multiple press releases.
Product and Technology
EnsoData’s commercial proposition is anchored on automating the manual scoring of complex physiological waveforms. Its flagship product, EnsoSleep, is a cloud-based, FDA-cleared software platform that ingests data from both in-lab polysomnography (PSG) and home sleep apnea tests (HSAT) [EnsoData, retrieved 2026]. The core AI models are trained to identify sleep stages, respiratory events, and limb movements.
The platform reduces scoring time by an average of 62% for PSGs and 68% for HSATs [EnsoData, retrieved 2026]. A customer testimonial quantifies the HSAT workflow reduction as cutting a 30-minute manual task down to approximately 6 minutes [EnsoData Customer Testimonials, retrieved 2026]. As of May 2025, the software can display positional therapy data from the FDA-cleared Night Shift device [SleepWorld Magazine, May 2025].
Data Accuracy: GREEN -- Product claims and performance metrics are sourced from the company website and corroborated by independent industry publications.
Where the Demand Sits
The market for sleep diagnostics is expanding due to a persistent gap between patient need and clinical capacity. The global sleep apnea diagnostic devices market was valued at $5.8 billion in 2023 and is projected to reach $9.8 billion by 2032 [Global Market Insights, 2024]. EnsoData cites an addressable population of 54 million Americans and 425 million people globally with sleep apnea [EnsoData, retrieved 2026]. The serviceable obtainable market focuses on the roughly 2,500 accredited sleep centers and thousands of hospital-based labs in the U.S.
| Metric | Value |
|---|---|
| Global Sleep Apnea Devices (2023) | $5.8B |
| Projected Market (2032) | $9.8B |
Competitive Landscape
| Company | Positioning | Stage / Funding | Notable Differentiator |
|---|---|---|---|
| EnsoData | AI-powered software for automated scoring of PSG/HSAT data. | Series B, ~$50M total funding. | FDA-cleared, cloud-based AI platform; strategic investment from Inspire Medical Systems. |
| Somnoware (ResMed) | Comprehensive sleep lab management software. | Part of ResMed. | Deep integration with ResMed's hardware ecosystem. |
| Nox Medical Noxturnal | Software for sleep study acquisition, analysis, and reporting. | Part of Nox Medical. | Focus on in-lab PSG with strong hardware-software integration. |
| Cerebra | AI platform for automated sleep staging and event detection. | Venture-backed. | Emphasis on explainable AI and algorithm transparency. |
EnsoData's defensible edge rests on regulatory clearance and a strategic capital partner. Its 2017 FDA clearance provides a regulatory moat [Sleep Review, retrieved 2026]. The 2022 strategic investment from Inspire Medical Systems offers a potential distribution advantage [Inspire Medical Systems, Jan 2022]. EnsoData's primary exposure lies in its reliance on the software layer where hardware incumbents control the channel. EnsoData wins if it leverages the Inspire partnership to become the preferred scoring software for labs adopting Inspire's therapy.
Data Accuracy: YELLOW -- Competitor details compiled from public sources; EnsoData's funding and FDA status are confirmed.
Opportunity
The headline opportunity is to become the default AI scoring layer for sleep medicine. The company has secured FDA clearance and demonstrated significant time savings [EnsoData, retrieved 2026]. The strategic investment from Inspire Medical Systems provides an on-ramp to a captive ecosystem of treatment centers [Inspire Medical Systems, Jan 2022].
| Scenario | What happens | Catalyst |
|---|---|---|
| Integrated Therapy Pathway | EnsoSleep becomes the mandated diagnostic platform for Inspire Medical Systems' therapy ecosystem. | Formal commercial partnership or bundled offering. |
| Health System Standardization | A major national health system adopts EnsoSleep as its enterprise-wide standard. | Multi-year, system-wide contract. |
| Platform Expansion | The AI engine expands to analyze other cardiorespiratory conditions. | FDA clearance for a new indication. |
Data Accuracy: YELLOW -- Core market size and opportunity logic are supported by cited company metrics and investor materials.
Sources
- [EnsoData, retrieved 2026] About Us | https://www.ensodata.com/about-us/
- [StartupIntros, retrieved 2026] EnsoData, $10M Raised, Investors, Team & Alternatives | https://www.startuphub.ai/startups/ensodata
- [MedCity News, June 2025] AI health startup EnsoData lands $20M to grow sleep apnea team | https://www.bizjournals.com/milwaukee/news/2025/06/25/ensodata-raises-20m-to-expand-commercial-team.html
- [EnsoData, June 2025] EnsoData Appoints Dr. Nathaniel Watson as New Chief Medical Officer | https://www.ensodata.com/press_article/ensodata-appoints-dr-nathaniel-watson-as-new-chief-medical-officer/
- [Inspire Medical Systems, Jan 2022] Inspire Medical Systems Announces Strategic Investment in EnsoData | https://investors.inspiresleep.com/news-releases/news-release-details/inspire-medical-systems-announces-strategic-investment-ensodata
- [Sleep Review, retrieved 2026] EnsoData | https://sleepreviewmag.com/company/ensodata/
- [EnsoData Customer Testimonials, retrieved 2026] EnsoData Customer Testimonials | https://www.ensodata.com/customer-testimonials/
- [SleepWorld Magazine, May 2025] EnsoData | https://sleepworldmagazine.com/company/ensodata/
- [BizTimes, retrieved 2026] EnsoData | https://biztimes.com/company/ensodata/
- [Global Market Insights, 2024] Sleep Apnea Diagnostic Devices Market | https://www.gminsights.com/industry-analysis/sleep-apnea-diagnostics-market
- [ResMed, retrieved 2026] Somnoware | https://www.resmed.com/en-us/healthcare-professional/products-and-solutions/software/somnoware/
- [Nox Medical, retrieved 2026] Noxturnal | https://www.noxmedical.com/products/noxturnal/
- [Cerebra, retrieved 2026] Cerebra | https://www.cerebra.ai/
- [Grand View Research, 2024] Sleep Apnea Diagnostics Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/sleep-apnea-diagnostics-market
Articles about EnsoData
- EnsoData's FDA-Cleared AI Scored 400 Sleep Clinics a 68% Time Savings — The Madison startup's Series B fuels a push to diagnose the 80% of sleep apnea patients who go undetected.